β¨ Trustee Appointment and Medicine Notices
18 JULY 2013 NEW ZEALAND GAZETTE, No. 91 2465
I am now pleased to appoint
Rakihia (Rick) Tahumata Tau
as a trustee of the Trust.
I consequently officially remove
Guy Richard Kiniwe Royal
from his position as a trustee of the Trust (published in the New Zealand Gazette, 21 April 2011, No. 55, page 1276).
Dated at Wellington this 23rd day of June 2013.
HON TIM GROSER, Minister for Climate Change Issues.
go4449
Health
Medicines Act 1981
Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23(1) of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Glycopyrronium Bromide 0.5mg/mL and Neostigmine Metilsulfate 2.5mg/mL Injection
Active Ingredients:
- Glycopyrronium bromide 0.5mg/mL
- Neostigmine metilsulfate 2.5mg/mL
Dosage Form: Solution for injection
New Zealand Sponsor: Max Health Limited
Manufacturer: Martindale Pharmaceuticals, Essex, United Kingdom
Note: This consent is valid for two years from the date of publication of this notice.
Dated this 11th day of July 2013.
DR DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go4469
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: AS-Pemetrexed
Active Ingredient: Pemetrexed disodium hemipentahydrate 604.12mg equivalent to pemetrexed 500mg
Dosage Form: Powder for infusion
New Zealand Sponsor: Agila (NZ) Pty Limited
Manufacturer: Onco Therapies Limited, Bangalore Karnataka, India
Product: GN-Pemetrexed
Active Ingredient: Pemetrexed disodium hemipentahydrate 604.12mg equivalent to pemetrexed 500mg
Dosage Form: Powder for infusion
New Zealand Sponsor: Agila (NZ) Pty Limited
Manufacturer: Onco Therapies Limited, Bangalore Karnataka, India
Product: Mylan-Bosentan
Active Ingredient: Bosentan monohydrate 64.541mg equivalent to bosentan anhydrous 62.5mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Mylan New Zealand Limited
Manufacturer: Mylan Laboratories Limited, Maharashtra State, India
Product: Mylan-Bosentan
Active Ingredient: Bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Mylan New Zealand Limited
Manufacturer: Mylan Laboratories Limited, Maharashtra State, India
Next Page →
β¨ LLM interpretation of page content
ποΈ Appointment and Removal of Trustee
ποΈ Governance & Central Administration23 June 2013
Trustee, Appointment, Removal, Climate Change Issues
- Rakihia (Rick) Tahumata Tau, Appointed as trustee
- Guy Richard Kiniwe Royal, Removed as trustee
- HON TIM GROSER, Minister for Climate Change Issues
π₯ Provisional Consent to the Distribution of a New Medicine
π₯ Health & Social Welfare11 July 2013
Medicine, Provisional Consent, Glycopyrronium Bromide, Neostigmine Metilsulfate
- DR DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health
π₯ Consent to the Distribution of New Medicines
π₯ Health & Social WelfareMedicine, Consent, Pemetrexed, Bosentan
NZ Gazette 2013, No 91